Exdensur is now the first twice-yearly add-on maintenance therapy approved for use in severe eosinophilic asthma.

GSK's asthma drug Exdensur, the first biologic for twice-yearly dosing, gains FDA approval for severe asthma treatment.

Dupixent For Moderate-To-Severe Asthma Treatment Market Expected To Reach ~$8.1 Billion By 2032. December 13, 2025 7:27 am - The Dupixent market for moderate-to-severe asthma is valued at $3.25 ...

The biotechnology sector is characterized by significant price swings, and Regeneron Pharmaceuticals is currently navigating one such period. Although the co ...

After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...

So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is included among the 14 Best US Stocks to Buy for Long Term. On December 4, ...

Kymera Therapeutics could have the next Dupixent, analysts said Monday, as shares skyrocketed on promising test results in ...

Now, the company will aim to show the drug helps patients with eczema and asthma in larger, placebo-controlled trial.

If you have ever wondered whether Regeneron Pharmaceuticals is a smart buy at around $718 a share, you are not alone; investors are trying to figure out if the current price really reflects its long ...

Interestingly, despite the autumn’s upward trend, November’s haul is the first in 2025 that doesn’t outweigh the ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $500.0 and $750.0 for Regeneron Pharmaceuticals, spanning the ...